Compare HI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HI | ANIP |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | HI | ANIP |
|---|---|---|
| Price | $31.98 | $76.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $32.00 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.0M | 459.0K |
| Earning Date | 02-04-2026 | 02-27-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.61 | ★ 1.67 |
| Revenue | ★ $2,673,800,000.00 | $826,880,000.00 |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | $2.62 | $11.25 |
| P/E Ratio | $52.46 | ★ $47.71 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $18.36 | $54.10 |
| 52 Week High | $35.48 | $99.50 |
| Indicator | HI | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 35.03 |
| Support Level | $31.84 | $78.38 |
| Resistance Level | $31.93 | $83.80 |
| Average True Range (ATR) | 0.05 | 2.77 |
| MACD | 0.00 | -0.45 |
| Stochastic Oscillator | 88.89 | 0.10 |
Hillenbrand Inc is a industrial company that provides engineered processing equipment and solutions to customers around the world. The company operates through two segments. The Advanced Process Solutions segment designs, develops, manufactures, and services engineered industrial equipment and also provider of engineered process and material handling equipment, systems, and aftermarket parts and services for a variety of industries, including durable plastics, food, and recycling. Molding Technology Solutions has a comprehensive product portfolio that includes injection molding and extrusion equipment, It earns it revenue from Advanced Process Solutions, and Geographically from America, following by Asia and EMEA.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.